At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Bavituximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy
In Brief
A Phase 2 clinical trial evaluating Bavituximab and Pembrolizumab Injection for Gastric Cancer and GastroEsophageal Cancer. Completed, enrolled 80 participants across 21 sites in 4 countries.
Detailed Summary
This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda. There is no expanded access program available for the investigational agents per this protocol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, GastroEsophageal Cancer
CountriesSouth Korea, Taiwan, United Kingdom, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedSep 2019
Primary CompletionDec 2021
Study CompletionOct 2022
TodayJul 2026
First PostedSep 23, 2019
Enrollment StartSep 11, 2019
Primary CompletionDec 20, 2021
Study CompletionOct 26, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.8 years ago
Interventions
Bavituximabdrug
Bavituximab IV infusion
Pembrolizumab Injectiondrug
Pembrolizumab IV Infusion